Connect with us

CBD

ACMD releases new advice on THC levels in consumer CBD products

The report suggests that the dose of each cannabinoid should not exceed 50 micrograms.

Published

on

Study finds CBD mislabelling taking place in US industry

A new report from the Advisory Council on the Misuse of Drugs (ACMD) has outlined its recommendations to the UK Government on establishing guidelines for the CBD industry

The ACMD published its recommendations for the appropriate levels of THC in individual servings of CBD, on Friday 17 December.

It has suggested that the dose of each controlled phytocannabinoid ‘should not exceed 50 micrograms per unit of consumption’,

The current limit is set as 0.2 or 0.3 per cent per serving of CBD, although many have debated that this is too low, with some other European counties already introducing a 0.05 per cent limit, such as the Netherlands.

Now, in the new report, the ACMD has said that an increase to 0.05 per cent was ‘unlikely to produce any harmful effects.’

It went onto suggest there may be a need for additional testing around the area of vaping to determine if CBD could, at extreme heat, be converted into THC.

The report follows the establishment of a working group by the ACMD to examine the appropriate levels of THC in products as well as advise the government on establishing a legal framework for CBD products.

The group consulted CBD industry professionals, analytical laboratories, reviewed literature and issued a public call for evidence. They also sought information regarding testing from the Government Chemist’s Team and Defence Science and Technology Laboratory.

The result was a series of recommendations including the THC-level increase. The report also noted that setting a single concentration limit to all consumer CBD products would not be appropriate.

Dr Parveen Bhatarah, regulatory and compliance lead at ACI  and CBC, met with the ACMD and consulted on the report.

Speaking with Cannabis Wealth, she said the ACMD has gone beyond what she was expecting.

“ACMD’s report released today is certainly a step in the right direction. I am so pleased that the ACMD team have accepted all our ACI recommendations, touching analytical, manufacturing, environmental and economic aspects of the CBD industry,” Dr Bhatarah commented.

Although she added that the ACMD has not clarified what the maximum dosage allowed should be.

“Speaking as a scientist, the limit of 50µg for Delta-9THC (combined with THA) in a single-serving of CBD consumer product needs little more clarity, as it could be open to misinterpretation without a maximum per day limit or similar,” she said.

“However, I do agree it has to be taken into account, with the maximum daily limit of no more than 70mg per day for CBD by FSA.”

Look out for further insight and reaction from the industry via Cannabis Wealth next week.

CBD

Italy passes decree that could put CBD farmers at risk of jail

Marco Perduca of Associazione Luca Coscioni says the decree puts Italy’s entire supply chain at risk.

Published

on

Italy passes decree which could put CBD farmers at risk of jail

Italy has passed a decree that prohibits the cultivation of CBD crops without authorisation from the country’s Ministry of Health.

CBD cultivation has been legal in Italy since 2016 after a unanimous vote in parliament. However, this month the Conference of State and Regions adopted a Ministerial Decree which now prohibits the crop’s cultivation.

Farmers, which until have been allowed to grow crops containing a limit of 0.2 to 0.5 per cent THC, will only be able to cultivate hemp crops unless given authorisation from the Ministry of Health. The ruling mirrors the current law surrounding the cultivation of higher THC cannabis crops for medical purposes.

With CBD available in shops across the country, the move is one in complete contrast to the direction of the rest of Europe, bar France, which recently passed a decree banning the sale of CBD flowers to consumers.

It will also put the entirety of Italy’s CBD supply chain at risk, says president of Italy’s cannabis referendum committee ReferendumCannabis and co-founder of Associazione Luca Coscioni, Marco Perduca.

Speaking to Cannabis Wealth, Perduca commented: “This has always been in the back of the centre right’s mind.

“The Ministerial Decree which is another vehicle to make law – even if it’s more on the administrative rather than and the lawmaking level – in which they re-included plans for reducing CBD under the regular rules set by the text on all drugs.”

ReferendumCannabis is currently trying to trigger a referendum to amend the wording of this text which would enable the personal cultivation of psychotropic substances.

“This will imply for those already in the business and the newcomers, to seek a permit from the Ministry of Health, which per se will not be a problem. But why would you have to ask, or re-ask permission for a well-established enterprise, to a ministry that has nothing to do with the oils, soaps and edibles that are produced using some CBD and a very minimal percentage of THC?” 

Perduca highlights a debate is set with the president of the Agriculture Committee on the matter.

“It’s an interpretation of the law. It is not opinion-makers that make interpretations of the law – it is a judge. So, if you have the police that come to your shop, or to your house or to your farm and would like to know more on what you are producing or selling, they can confiscate everything and block your activity until further notice. 

“This is an additional burden on an already not-working system of justice. It is also a sort of CBD scare that has been launched against in particular shops and entrepreneurs – about 10,000 people that work in 3000 Small and Medium Enterprises which generate around €40m per year. 

“It’s an important part of our agricultural economy, and it’s mainly young people that invest in these kinds of enterprises.’

Together with Leonardo Fiorentini, member of  Forum Droghe, Perduca stated that the discussion of the decree took place days following the first meeting between the Ministry of Health and the country’s cannabis patient associations to discuss supply requirements. 

They stated: “The version in front of the delegates risks canceling, if not sending to jail, the entire cannabis light [CBD] sector in Italy…

“The World Health Organization has repeatedly recommended the exclusion of the properties of CBD from banned substances, some of these were collected by the UN Drugs Commission which in December 2020 canceled cannabis from the IV table of the 1961 Convention with a vote favourable of Italy. 

“To insert this submission of production to the rules of 309/90 with a Ministerial Decree, as well as going against common sense, is legally very questionable. Certainly, we need a regulation that clarifies what it can be cultivated and how to guarantee the quantity and quality of therapeutic cannabinoids necessary to guarantee the therapeutic plans of tens of thousands of people: products with a certain threshold of CBD must be treated as drugs, those below as supplements, as is already the case today for many other substances also in other EU states.

“We appeal to the competent Ministers to amend the Decree to art. 1 paragraph 4. If not, we will organize a coordinated response between patients and entrepreneurs to definitively send anti-scientific and ideological measures to the attic.” [translated from Google]

Continue Reading

CBD

CBD-brand MYO launches in Boots across the UK

MYO will be available in 838 Boots stores across the country.

Published

on

CBD-brand MYO launches in Boots across the UK

CBD-brand MYO has hit a major milestone in its journey with a new partnership that will see its products stocked in the leading UK health and beauty retailer’s stores.

Boots will stock MYO‘s Plant Proteins in 838 stores, branched-chain amino acids and essential amino acids in up to 574 stores, and functional sprays in 522 stores.

MYO, acquired by global vertically integrated wellness platform Yooma Wellness in March 2021, is one of the few brands whose CBD products have passed the UK Food Standard Agency’s (FSA) validation assessment.

James Lawson Baker, Founder of MYO Plant Nutrition, commented: “This is a major milestone for MYO and we are absolutely delighted to be partnering with Boots, the leading health and beauty retailer in the UK.

“A listing of this size gives the brand enormous national exposure and deepens our footprint within mainstream UK retail.

Read more: Yooma: building a vertically integrated CBD and wellness platform

“The listing will support MYO in making plant-based active nutrition and wellness products mainstream and accessible.

“The partnership is a testament to the high-quality product and brand offering that we have built over the past year.  We look forward to building our credibility amongst Boots’ customers going forward.”

The product listing with Boots adds to its list of retail chains where its products are available, including Holland & Barrett, Selfridges, Lloyds Pharmacy and Amazon.

Jordan Greenberg, CEO of Yooma, commented: “MYO Plant Nutrition is an exceptional example of how Yooma’s buy-and-build strategy creates shareholder value.

“MYO continues to surpass expectations with its increased availability in UK’s most reputable retailers and it has the honour of being known as one of the few brands to have passed the FSA’s validation assessment.”

Continue Reading

CBD

British Cannabis celebrate products receiving confirmation from FSA

British Cannabis is dedicated to ensuring the long-term continuity of cannabis-based food supplements in the UK

Published

on

British Cannabis products receive confirmation of being the first Cannabis-derived CBD oils and supplements set to remain on the market

British Cannabis™, registered as CBD Health Foods Ltd, is delighted to become the first company to receive confirmation from the Food Standards Agency UK (FSA). that its cannabis-derived products will remain on the market.

On Thursday 13th January 2022, the FSA confirmed via emails to British Cannabis CEO, Thomas Whettem, that the evidence submitted in support of 15 dossiers, spanning over 3,000 products “has been checked and is sufficient” and that “the public list will be amended to reflect these changes”.

British Cannabis’ own-brand products – CBD by British Cannabis (FKA Canabidol™), Access CBD™ and CBD Health™ plus over 150 other brands that they manufacture for, look set to remain on the UK market.

Meanwhile, it is widely speculated that an as-yet-undetermined number of other products, made by other manufacturers, will be removed from shelves by Trading Standards. This process looks set to begin once the FSA public lists are updated later in 2022.

British Cannabis products

Robert Jappie, the partner at legal firm Ince and preeminent cannabis industry lawyer, remarked at the news: “I’m delighted that British Cannabis has received a positive response from the FSA to their Novel Food submission. Admission of British Cannabis’ products to the compliance registers confirms the company’s position at the forefront of the U.K. CBD industry. Novel Food compliance should now provide a platform for the sector to build on its fantastic success to date.”

Over the course of 18 months and a multi-million-pound investment, British Cannabis, whose brands are stocked across many pharmacies and retailers internationally, have dedicated themselves to ensuring the long-term continuity of all-natural, cannabis-based food supplements in the UK. This is for the reassurance of their own consumers and of all the customers whose brands are powered by British Cannabis.British Cannabis: a collection of products

Cannabis market

Making this achievement of particular note is the fact that British Cannabis products are among the few remaining on the market to use ‘100 per cent Cannabis sativa L.”, naturally derived formulas, thus they contain the hundreds of clinically proven plant phytochemicals found in cannabis, whilst also being 0 per cent THC, meaning that they will not cause a “high”. Their food supplements (CBD oils, capsules etc.) are also free from other controlled cannabinoids.

British Cannabis’ CEO, Thomas Whettem, reacted shortly after hearing the great news: “Confirmation directly from the Food Standards Agency, that British Cannabis will be the first manufacturer In the world to have cannabis-derived consumer products ratified by the UK government, is yet another monumental breakthrough in our history. For years we have not just pioneered change in this industry but strived to set the bar when it comes to compliance, safety and the simple dedication to excellence we have had since day one.”

British Cannabis’ Managing Director, David Ralson, commented on this landmark news: “This is a huge milestone for our business and the Cannabis industry as a whole. I would firstly like to pay testimony to our staff, who over the past 6 years have endeavoured to make British Cannabis the leading legal-cannabis experts in our sector and this exemplifies our phrase ‘’We Know More Because We Do More’’.

We have always believed in wholly cannabis-derived, natural products and obtaining the highest quality standards. This is underpinned by our own retail brands, which to date have received over 4,200 Trustpilot reviews with a 5-Star rating.
This also paves the way for our trusted white label partners brands, who continue to work with us, to also remain on the UK market. This allows our business and its compliant partners to continue to grow in what is going to be a very exciting year indeed.”

At the time of release, the Novel Foods public lists have yet to be updated.

 

Continue Reading
Sign up for the Cannabis Wealth newsletter

Recent Posts